纳米技术介导的Ingenol-3-Mebutate免疫Chemotherapy 的系统性Anti-tumor
瑞禧生物2025-02-13   作者:ws   来源:
字号大小:

文献:Nanotechnology-mediated immunochemotherapy with Ingenol-3-Mebutate for Systematic Anti-tumor Effects

文献链接:

https://www.sciencedirect.com/science/article/abs/pii/S016836591930255X

作者:Mian Yua, Miaoqing Zhao, Rilei Yua, Shaochen Chua, Jiahao Xua, Ming Xiad,Cheng Wang

相关产品:Cy7 labeled I3A

原文摘要:

 Cancer-Immunotherapy was the most exciting topic. However, either insensitivity due to singleness of therapeutic target or immune evasion leads to the failure of the treatment. Ingenol-3-mebutate (I3A) can inhibit cancer through synergy between immunotherapy and chemotherapy, however, the speculation and accurate mechanism haven't been confirmed in vivo limited by its hydrophobicity and pH-instability, which also hindered its clinical translation. Herein we developed a polymeric micelle with ‘acidic core’ provided by single alcoholic hydroxyl (-CH(CH3)-OH) encapsulating I3A (I3A-PM), which successfully overcome the aforementioned problems and reduce the toxicity in vivo. To test the synergy, S180 tumor-bearing mice were subjected to I3A-PM through intravenous and intratumoral administration, we found I3A-PM presented significant antitumor effect,and promoted Th1 polarization by upregulating the level of Th1 cytokines (IL-12, IL-2, IFN-γ and TNF-α), and accelerated the expansion of CD4+ and CD8+ T cells, meanwhile, I3A-PM depleted regulatory T cells, Th2 cytokine IL-6 through inhibiting TGF-β signaling pathway. Furthermore, we appealed to virtual screening of tumor target, and found a new pathway of I3A as a TGF-β receptor type I inhibitor to improve immunostimulatory effects. These results demonstrated I3A-PM as a promising nanoagent for cancer immunotherapy strategy. The synergistic therapeutic effects are encouraged to further evaluate in different cancer model compared with commercial products to facilitate research finding (I3A-PM) entering the clinic.  

 

Cy7 labeled I3A:Cy7 是一种荧光染料。Cy7 属于花菁染料(Cyanine Dyes)家族,它的最大吸收波长在 750 - 770nm 左右,发射波长在 780 - 800nm 左右,在近红外光区有很好的荧光性能。这种近红外荧光特性使得它在生物成像等领域很有优势,因为生物组织在近红外波段的自发荧光相对较弱,能减少背景干扰,提高检测的灵敏度和分辨率。I3A指一种化合物, 3 - 吲哚甲醛(indole - 3 - carbaldehyde)。“labeled” 表示标记的意思,即 I3A 这个分子被 Cy7 染料进行了标记。基于Cy7 labeled I3A的性能,介绍如下:

 

作用机制 

图:作用机制

 

Cy7 labeled I3A标记I3A-PM:

 I3A - PM 的预处理:如 I3A - PM 表面有杂质或者需要激活某些官能团才能进行标记反应,需要进行预处理。例如,如果 I3A - PM 是纳米颗粒,可能需要用缓冲溶液洗涤几次,去除表面的稳定剂或其他杂质。

标记反应:如果是直接标记 I3A - PM,反应步骤与 I3A 的标记类似。将 I3A - PM 分散在缓冲溶液中,加入 Cy7 染料溶液,控制合适的摩尔比、反应温度和时间进行标记反应。如果是将标记后的 I3A 与 I3A - PM 结合,需要考虑两者的结合方式。例如,如果是通过静电相互作用结合,要确保反应体系的 pH 和离子强度有利于静电吸附。可以将标记后的 I3A 溶液缓慢加入到 I3A - PM 分散液中,在温和搅拌或涡旋混合的条件下反应。

反应后处理:反应结束后,离心收集标记后的产物。用缓冲溶液洗涤几次,去除未反应的 Cy7 染料和 I3A。

 

电镜图像 

图:电镜图像

 

结论:

该文献成功制出I3A-PM,Cy7 labeled I3A成功标记了I3A-PM,方便后续实验的进行。实验使用成像系统实时监测 I3A - PM 在体内的动态分布,观察富集情况,判断靶向作用的情况。结果表明,I3A-PM可作为一种有前途的cancer免疫Treatment 策略的纳米化合物。